A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 31 Oct 2017 The study has been completed in Germany (End Date:2017-08-24).
- 30 Sep 2017 The study has been completed in Spain (End Date:2017-08-24).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History